Clinical Trials Browser

Active not recruiting × INDUSTRY × Albumin-Bound Paclitaxel × Clear all

NCT05771480 2026-04-21

TOURMALINE

Phase 3 Active not recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT05382299 2026-04-06

ASCENT-03

Phase 3 Active not recruiting

Triple Negative Breast Neoplasms

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Phase 2 Active not recruiting

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT06132958 2026-04-03

TroFuse-005

Phase 3 Active not recruiting

Endometrial Neoplasms

NCT04104672 2026-03-31

ARC-8

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05017012 2026-03-27

MK-3475A-C18

Phase 1 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03164616 2026-03-13

POSEIDON

Phase 3 Active not recruiting

1,186 enrolled 26 charts 2 FDA

Non Small Cell Lung Cancer NSCLC

NCT06704724 2026-03-13

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Phase 1 Active not recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT04895358 2026-03-11

KEYNOTE-B49

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting

Solid Cancer

NCT04396821 2025-12-17

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

Phase 1/2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms

NCT06212752 2025-11-12

MK-3475A-D77

Phase 3 Active not recruiting

39 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT05840211 2025-10-03

ASCENT-07

Phase 3 Active not recruiting

Breast Neoplasms

NCT05382286 2025-09-18

ASCENT-04

Phase 3 Active not recruiting

Triple Negative Breast Neoplasms

NCT05722015 2025-09-11

MK-3475A-D77

Phase 3 Active not recruiting

377 enrolled 17 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT05669482 2025-09-02

RAMP205

Phase 1/2 Active not recruiting

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT02340117 2025-05-30

Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06390059 2025-04-30

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT03252808 2024-12-09

Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04956692 2024-12-03

MK-3475-A86

Phase 3 Active not recruiting

531 enrolled 18 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04589234 2024-04-24

Saltikva for Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms